Gallid herpesvirus 2 (ATCC® VR-2260)

Classification: Herpesviridae, Mardivirus  /  Product Format: frozen

Classification Herpesviridae, Mardivirus
Deposited As Marek's disease virus type 1
Agent Gallid herpesvirus 2
Strain CVI-988 CEF65 clone C/R6 CEF14
Biosafety Level 2
Isolation
Patent 4,673,572; Rispens, B.H. et al., Avian Dis. 16: 108-125, 1972
Product Format frozen
Storage Conditions Liquid nitrogen vapors
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
Very cell-associated CPE foci
Recommended Host
chicken embryo fibroblasts; chicken

Host of Choice:   SL-29 (ATCC CRL-1590)

Host Range: SL-29 (ATCC CRL-1590) and C

Growth Conditions
Temperature: 37.0°C
Duration: 3-5 days
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
Very cell-associated CPE foci
Name of Depositor Central Vet. Res. Inst.
Source
Patent 4,673,572; Rispens, B.H. et al., Avian Dis. 16: 108-125, 1972
Year of Origin 1972
References

DeBoer GF. Live purified Marek's disease vaccine. US Patent 4,673,572 dated Jun 16 1987

Rispens BH, et al. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 16: 108-125, 1972. PubMed: 4337307

Rispens BH, et al. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis. 16: 126-138, 1972. PubMed: 4337309